skip to main content

Anti-NXP2 Clinical — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardMyositisAnti-NXP2 ClinicalSCE Rheumatology

A 52-year-old with new dermatomyositis has anti-NXP2 antibodies, dysphagia and severe active disease. How should malignancy risk be classified?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — High risk, prompting basic and enhanced screening at diagnosis

Adult-onset dermatomyositis, anti-NXP2 positivity, age over 40, dysphagia and severe activity are IMACS high-risk factors. The patient needs basic and enhanced screening at diagnosis and risk-based follow-up, not antibody interpretation in isolation.

Reference: IMACS international guideline for inflammatory-myopathy-associated cancer screening (Published November 2023): https://www.nature.com/articles/s41584-023-01045-w; BSR guideline for idiopathic inflammatory myopathy in children and adults (Published April 2022): https://academic.oup.com/rheumatology/article/61/5/1760/6555980